Navigation Links
WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Date:3/1/2011

BOTHELL, Wash., March 1, 2011 /PRNewswire/ -- Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated at Overlake Hospital Medical Center in Bellevue and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including thousands of deaths.  Studies have shown that DNA testing can dramatically improve the safety and effectiveness of warfarin, with estimated savings to the U.S. healthcare system of approximately $1.1 billion.Warfarin is prescribed to 2 million patients in the U.S. annually and approximately 20 million Americans use the drug in total.  Warfarin is difficult to dose as patients respond to it differently according to their genetic makeup -- too much warfarin can result in severe bleeding, and too little can cause clot formation and increased risk of stroke.  In the past, warfarin dosing relied on trial-and-error, which exposed patients to serious medical risks.  Warfarin is the second most frequent cause of drug-related emergency room visits.  

"Safeguarding the health of our citizens is always a top priority of government," said Rogers Weed, Director of the Washington State Department of Commerce. "The WARFARIN Study aims to demonstrate that using genetic testing for warfarin dosing can improve patients' overall health, save lives and lower healthcare costs here in Washington as well as nationwide. As a leader in advancing genetically-based medical practice, Washington is proud that a local company and one of our state's premier hospitals are taking the lead in this innovative research."

Over the past few years, two genetic variants have been identified that predict an individual's response to warfarin.  Using genetic testing to guide physicians in starting warfarin therapy has the potential to reduce deaths, increase overall patient safety and lower national healthcare system costs.  Given the magnitude of these potential improvements in warfarin use, the Centers for Medicare & Medicaid Services (CMS) has authorized the WARFARIN Study to gather data on the potential impact of a pharmacogenetic test to reduce serious bleeding and clotting episodes in patients.  Upon review of the Study, the first such personalized medicine trial authorized by CMS, the agency may establish reimbursement for the genetic warfarin test, which is marketed by Iverson Genetic Diagnostics.  

Leroy Hood, M.D., Ph.D., co-founder of the Institute for Systems Biology and a member of Iverson Genetic Diagnostics' Board of Directors, commented, "The technological tools for molecular discovery that we continue to develop become truly valuable when they can actually improve human health.  CMS is to be commended for its leadership in authorizing the WARFARIN Study.  This study marks a step towards our goal of improving patient outcomes through personalized care."Researchers have identified two specific genes, VKORC1 (for warfarin sensitivity) and CYP2C9 (for warfarin metabolism), which contribute up to 40% of individual patient variations in response to using warfarin. The WARFARIN Study will assess the extent to which serious adverse events – hemorrhage and clotting – can be avoided when warfarin dosing is guided by genetic testing for these two genes, as compared to warfarin dosing calculated without these pharmacogenetic data.  

"Overlake Hospital Medical Center is one of the key sites in the national WARFARIN Study, which altogether will enroll more than 7,000 patients across the country," said Kathleen D. Gibson, MD, a partner at Lake Washington Vascular Surgeons and the Site Principal Investigator for the WARFARIN Study at Overlake Hospital Medical Center.  "We are delighted to be an integral part of this research, and hope the data we contribute from Overlake will help improve patients' lives for years to come."

The 18-month study will determine patients' rates of warfarin-related adverse events at 30, 60 and 90 days from initial warfarin dosing.  Study results will be used by CMS for reimbursement decision-making.  The multicenter, randomized, blinded, parallel-group study is being led by Principal Investigator Elizabeth Ofili, M.D., Chief of Cardiology, Director of Clinical Research, and Associate Dean for Clinical Research at Morehouse School of Medicine.  Trial registration and study sites can be found at www.warfarinstudy.org.  

"This landmark study is about more than warfarin," said Dean Sproles, CEO and Chairman, Iverson Genetic Diagnostics Inc., which initiated the WARFARIN Study.  "It is about individualizing treatment to improve patient safety and outcomes, thereby reducing healthcare costs.  CMS' support of the WARFARIN Study demonstrates their commitment to exploring the impact of genetic testing on individualized dosing, which may pave the way for other studies in the personalized medicine arena."

In related news, Mr. Sproles will make a presentation on March 2, 2011, about the newly-launched WARFARIN Study at the 11th Annual Life Science Innovation Northwest Conference, sponsored by the Washington Biotechnology & Biomedical Association (WBBA) in partnership with Burrill & Co.  He will present at 2:35 pm in Room 608, Washington State Convention Center, Seattle, WA.  

About Iverson Genetic Diagnostics, Inc.Iverson Genetic Diagnostics, Inc. provides physicians with genetics-based testing to identify individual patients' predispositions to major diseases as well as the therapeutic considerations that can improve treatment outcomes and quality of life.
With its growing portfolio of genetics-based tests and assays, the company is addressing one of today's major medical challenges by ushering in a new era of more timely, predictive, and affordable "personalized" healthcare.  The Company markets the Warfarin GenoSTAT Test® to provide personalized genetic profiles of patients' potential responses to treatment with warfarin.  Iverson Genetic Diagnostics is headquartered in Bothell, Washington, part of the greater Seattle technology corridor.  The company's facilities are CLIA- and CAP-certified.  For more information, visit  www.IversonGenetics.com.Lynn Blenkhorn508-851-0930Lynn.blenkhorn@fkhealth.com
'/>"/>

SOURCE Iverson Genetic Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic information personalizes warfarin prescribing
2. Pivotal Study Validates Roches cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
3. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
4. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
5. Study Confirms Third Trimester Amniotic Fluid a Reliable Source of Stem Cells for Regenerative Medicine and Stem Cell Banking
6. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
7. New test to study proteins involved in neurodegenerative diseases
8. A new model for studying Parkinsons
9. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
10. Columbia University researchers use nanoscale transistors to study single-molecule interactions
11. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... light to control cells — optogenetics — is key to exciting advances in ... the art, spatially patterned light projected via free-space optics stimulates small, transparent organisms ...
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review ... biotech crops. The authors focus on the economic effects in countries that are major ... new biotech crops and the resultant risk of low level presence (LLP) puts large ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
Breaking Biology Technology:
(Date:12/7/2016)... Israel , December 7, 2016 BioCatch ... the expansion of its patent portfolio, which grew to over 40 granted ... , , ... its recently filed patent entitled " System, Device, and Method ... technology that enables device makers to forego costly hardware components needed to ...
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
Breaking Biology News(10 mins):